Mesoblast Limited (MESO)
Chart Events
Performance Outlook
| Previous Close | 3.5300 |
| Open | 3.5900 |
| Bid | 3.6100 x 1400 |
| Ask | 3.6800 x 800 |
| Day's Range | 3.5220 - 3.6600 |
| 52 Week Range | 3.2300 - 8.8500 |
| Volume | |
| Avg. Volume | 73,333 |
| Market Cap | 469.654M |
| Beta (5Y Monthly) | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7650 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MESO
Related Research
- Mesoblast LimitedDaily – Vickers Top Buyers & Sellers for 11/24/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat6 months agoArgus Research
- Simply Wall St.
Perenti Global (ASX:PRN) shareholders have endured a 44% loss from investing in the stock three years ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
- Simply Wall St.
What Type Of Shareholders Make Up Mesoblast Limited's (ASX:MSB) Share Registry?
The big shareholder groups in Mesoblast Limited ( ASX:MSB ) have power over the company. Institutions will often hold...
- GlobeNewswire
Appendix 4C Quarterly Activity Report
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2022NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2022. Financial highlights Net cash usage for operating activities in the quarter was reduced by 40%, or US$10.3 million, to US$15.5 million compared with US$25.8 million in the comparativ
